Iavazzo Christos, Fotiou Alexandros, Kokkali Kalliopi, Vorgias George
Gynecologic Oncology Department, "Metaxa" Memorial Cancer Hospital of Piraeus, Piraeus, Greece.
Cancer Diagn Progn. 2023 May 3;3(3):392-397. doi: 10.21873/cdp.10230. eCollection 2023 May-Jun.
BACKGROUND/AIM: Ovarian cancer remains one of the most lethal malignancies in women. Optimal surgical cytoreduction is the most important prognostic factor of survival in patients with advanced ovarian cancer. The helium gas plasma device (J-Plasma) has recently been introduced into surgical treatment of these patients with some promising results. The aim of this study was to evaluate the utility of J-Plasma in the debulking surgery of patients with ovarian cancer.
A single center retrospective analysis of the characteristics of patients with ovarian cancer who had cytoreductive surgery with the use of J-Plasma device from January of 2020 until July of 2022 was conducted.
A total of 13 patients were included in our study. Six patients were treated with primary debulking surgery, whereas seven underwent interval debulking surgery after neoadjuvant chemotherapy. Complete cytoreduction was achieved in nine patients (64%), and CC-1 in four patients. Most of the patients did not face any major complications; only 1 patient suffered from small bowel fistula that needed relaparotomy.
J-Plasma can safely be used in ovarian cancer debulking surgeries performed by gynecologic oncologists in tertiary centres. This technology can safely increase the complete cytoreduction rates.
背景/目的：卵巢癌仍然是女性最致命的恶性肿瘤之一。最佳的手术细胞减灭术是晚期卵巢癌患者生存的最重要预后因素。氦气等离子体设备（J-Plasma）最近已被引入这些患者的手术治疗中，并取得了一些有前景的结果。本研究的目的是评估J-Plasma在卵巢癌患者肿瘤细胞减灭术中的效用。
对2020年1月至2022年7月期间使用J-Plasma设备进行细胞减灭术的卵巢癌患者的特征进行了单中心回顾性分析。
本研究共纳入13例患者。6例患者接受了初次肿瘤细胞减灭术，而7例在新辅助化疗后接受了间隔性肿瘤细胞减灭术。9例患者（64%）实现了完全细胞减灭，4例患者实现了CC-1。大多数患者未出现任何严重并发症；只有1例患者发生小肠瘘，需要再次剖腹手术。
J-Plasma可安全地用于三级中心妇科肿瘤学家进行的卵巢癌肿瘤细胞减灭术。这项技术可以安全地提高完全细胞减灭率。
